The idea of co-targeting ERα and PARP1 is supported by reports that showed that a combination of tamoxifen and talazoparib sensitized breast cancer cells to tamoxifen through the reduction of ERα poly-ADP-ribosylation [27]. Here, PARP1 is linked to breast carcinoma.